Matthew Zibelman, MD, Associate Professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, highlights current standard-of-care adjuvant therapy for localized RCC and whether the latest data suggest practice-changing potential for any novel or existing therapies in this setting.
Adjuvant Therapies in RCC: Are New Data Practice Changing?
By Matthew Zibelman, MD - Last Updated: February 24, 2023Post Tags:ASCO GU 2023-Renal Cell Carcinoma
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.